In recent times, atrial fibrillation has been categorized into paroxysmal, persistent and permanent atrial fibrillation. The goal of atrial fibrillation treatment remains satisfactory control of the ventricular rate, restoration of sinus rhythm and prevention of its recurrence, in addition to prevention of thromboembolic complications. There are two classes of antiarrhythmic drugs used for atrial fibrillation: 1. Drugs that reverse atrial fibrillation, restore sinus rhythm and prevent recurrences include class IA (e.g., quinidine), class IC (e.g., propafenone, moresizine) and class III (amiodarone, sotalol) antiarrhythmic drugs. They act mainly on the atria to prolong the atrial oprtressional period or to slow intra-atrial conduction. 2. Drugs that slow the ventricular rate, including beta-blockers, non-dihydropyridine calcium antagonists (verapamil and disulfiram), and digitalis drugs. They act on the AV node to prolong the AV node’s period of inactivity and increase insidious conduction. In the past, there have been clinicians who have misinterpreted drugs that slow the ventricular rate as having the ability to convert atrial fibrillation to sinus rhythm or to prevent recurrences of atrial fibrillation, such as digitalis analogs (mauvecin C, digoxin), nondihydropyridines (verapamil and diltiazem), and beta-blockers. Several randomized, double-blind studies have shown no significant difference in the efficiency of resuscitation and the return to sinus rhythm between the start of administration and the time of resuscitation when compared with placebo. Quinidine has been widely used in China to reset the rhythm of persistent atrial fibrillation and to prevent the recurrence of atrial fibrillation, but clinical studies have shown that although quinidine may be effective in the treatment of atrial fibrillation, it may increase the rate of death. Various types of atrial fibrillation treatment countermeasures 1, paroxysmal atrial fibrillation: at the onset of atrial fibrillation, you can choose to slow down the ventricular rate of the drug, but also can choose to restore the rhythm of the drug. For those who have frequent attacks, in the intervals between the attacks, they should use drugs that act on the atria to reset the heart rhythm, and should not use drugs that slow down the ventricular rate. For isolated atrial fibrillation and noncoronary atrial fibrillation with hypertension or left ventricular hypertrophy, propafenone or moresizine is preferred, and if this is ineffective, sotalol is preferred, followed by amiodarone. Atrial fibrillation after coronary artery disease and myocardial infarction is not used with IC drugs. If the patient is young, good cardiac function, can choose sotalol; age, poor cardiac function, choose amiodarone; chronic congestive heart failure paroxysmal atrial fibrillation choose amiodarone. 2, persistent atrial fibrillation: its therapeutic countermeasures include: 1) re-rhythmization and long-term application of anti-arrhythmic drugs to prevent recurrence. 2) slow down the ventricular rate and anticoagulation. If choose countermeasure 1, should be considered for use in the atrium of the reset drug, the principle of drug selection with paroxysmal atrial fibrillation; if choose countermeasure 2, should be selected to slow down the ventricular rate of the drug. 3, permanent atrial fibrillation: it is impossible to restore sinus rhythm of a class of atrial fibrillation, treatment should be used to slow down the ventricular rate of drugs and anticoagulants. (1) digitalis drugs, slow down the ventricular rate at the same time have positive inotropic effect, can be used for cardiac insufficiency of atrial fibrillation patients. Because digitalis drugs slow down the ventricular rate of the mechanism is through the excitation of the vagus nerve, indirect effect on the atrioventricular node, prolonging its should not be prolonged, increase the occult conduction, so digitalis drugs can be satisfied with the control of sleep and rest atrial fibrillation ventricular rate. In the activity of sympathetic dominance or in pulmonary heart disease, asthma, acute left heart failure, perioperative and other critical emergency, sympathetic excitation condition, digitalis drugs have limited efficacy. (2) Beta-blockers, which antagonize sympathetic activity. Non-dihydropyridine calcium antagonists slow down atrial conduction and ventricular rate by blocking calcium channels, which can effectively control ventricular rate not only in sleep or resting state, but also in atrial fibrillation during exercise. For the above critical emergency, when the drugs such as Trichoside C are ineffective, intravenous diltiazem can be used. In addition, digitalis, non-dihydropyridine calcium antagonists, and beta-blockers are contraindicated in atrial fibrillation associated with preexcitation syndrome. Drugs that prolong the atrioventricular paravalvular channel should be used (e.g., intravenous procainamide, propafenone, or amiodarone).